Morgan Stanley downgraded Mural Oncology (MURA) to Equal Weight from Overweight and removed the firm’s prior $13 price target after removing the platinum-resistant ovarian cancer indication for nemvaleukin from the firm’s model following the company having announced interim results of the Phase 3 ARTISTRY-7 trial. The firm now looks toward topline data from ARTISTRY-6 in mucosal melanoma in Q2 in order to assess the viability of Mural’s lead asset, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MURA:
- Promising Developments in Mural Oncology Plc’s ARTISTRY-7 Trial Boost Buy Rating
- Promising Outlook for Mural Oncology: Buy Rating Driven by Nemvaleukin’s Potential and Strategic Trials
- Mural Oncology Highlights 2024 Financial Results and Strategic Focus
- Mural Oncology reports Q4 EPS ($2.01), consensus ($1.96)
- Promising Prospects for Mural Oncology: Buy Rating Justified by Strong Pipeline and Financial Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue